MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/rlu.0000000000006014

Медицинская библиотека · Clinical nuclear medicine · 2025

First-in-Human Evaluation of [ 18 F]AldoView: A Highly Selective PET Tracer for Aldosterone Synthase Imaging in Primary Aldosteronism.

Long Tingting, Liu Geru, Zhou Ming, Zhang Zhen, Xiao Yao, Chen Huizhu, Peng Ning, Jin Yuzhen, He Yao, Gan Yu, Chen Zhi, Luo Min, Li Chun, Xiao Yuan, Liu Zehao, Guo Min, Xia Zhuying, Wang Min, Wang Jing, Liu Longfei, Luo Xianghang, Jiang Tiejian, Hu Shuo

СтатьяКлиническое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Aldosterone synthase (CYP11B2) is overexpressed in primary aldosteronism (PA), making it a promising target for imaging. This first-in-human study evaluates the safety and feasibility of [ 18 F]AldoView, a highly selective PET tracer targeting CYP11B2, for PA subtyping.

METHODS

Biodistribution and dosimetry of [ 18 F]AldoView were assessed in 3 healthy volunteers using whole-body PET/CT. Fifteen patients with adrenal lesions (13 with PA, 1 with Cushing's syndrome, and 1 with a nonfunctional adenoma) were enrolled. PET/CT scans were performed 60 minutes postinjection. Lesions were considered positive if tracer uptake exceeded normal adrenal tissue. Semi-quantitative analyses included maximum standardized uptake value (SUVmax), lesion-to-liver ratio (LLR), and lesion-to-adrenal ratio (LAR). Ten PA patients with positive imaging findings and 1 with Cushing's syndrome underwent adrenalectomy, and resected specimens were analyzed for CYP11B2 expression. This ongoing study is registered with the Chinese Clinical Trial Registry (ChiCTR2400093214).

RESULTS

[ 18 F]AldoView was well-tolerated, with no adverse events. The effective dose was 0.012±0.0022 mSv/MBq. PET/CT identified positive lesions in all 10 PA patients, with a mean SUVmax of 15.73±8.57, LAR of 8.02±4.06, and LLR of 10.24±1.48. No positive lesions were observed in patients with idiopathic hyperaldosteronism, Cushing's syndrome, or nonfunctional adenomas. Positive lesions showed strong CYP11B2 staining on pathology, confirming aldosterone-producing adenomas (APA) or nodules (APN).

CONCLUSIONS

[ 18 F]AldoView PET/CT is safe and feasible for the imaging of APAs and APNs in PA patients. These results highlight its potential for noninvasive in vivo detection of CYP11B2, supporting its use in PA subtyping.

Для цитирования: Long Tingting, Liu Geru, Zhou Ming, Zhang Zhen, Xiao Yao, Chen Huizhu, Peng Ning, Jin Yuzhen, He Yao, Gan Yu, Chen Zhi, Luo Min, Li Chun, Xiao Yuan, Liu Zehao, Guo Min, Xia Zhuying, Wang Min, Wang Jing, Liu Longfei, Luo Xianghang, Jiang Tiejian, Hu Shuo. First-in-Human Evaluation of [ 18 F]AldoView: A Highly Selective PET Tracer for Aldosterone Synthase Imaging in Primary Aldosteronism.. Clinical nuclear medicine. 2025. DOI: 10.1097/rlu.0000000000006014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.